Combination of anti-claudin 18.2 / anti-4-1bb antibodies and a second therapeutic agent in the treatment of cancer

CL202600885A1Pending Publication Date: 2026-07-31I MAB BIOPHARMA US LTD +1

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CL202600885
Authority / Receiving Office: CL · CL
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-09-27
Filing Date: 2026-03-25
Publication Date: 2026-07-31

Application Information

Patent Timeline

27 Sep 2024

Priority

25 Mar 2026

Application

CL202600885

31 Jul 2026

Publication

CL202600885A1

IPC: A61K39/395; A61P35/00; C07K16/28; C07K16/46

CPC: C07K16/28; A61P35/00; C07K16/2878; C07K2317/31; C07K2317/73; A61K39/3955; A61K2039/505; A61K2300/00

Inventors: LIU Xuejun; WANG Zhengyi

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The combined use of bispecific and multispecific antibodies targeting both claudin 18.2 (CLDN18.2) and 4-1BB with a second therapeutic agent is provided in the treatment of cancer.

Need to check novelty before this filing date? Find Prior Art